Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Interest & Investment Income (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Interest & Investment Income over the past 3 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $1.3 million for Q4 2025, up 134300.0% from a year ago — trailing twelve months through Dec 2025 was $3.5 million (up 12933.33% YoY), and the annual figure for FY2025 was $4.1 million, up 18745.45%.
  • Interest & Investment Income for Q4 2025 was $1.3 million at Tonix Pharmaceuticals Holding, up from $1.2 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for TNXP hit a ceiling of $1.3 million in Q4 2025 and a floor of $1000.0 in Q2 2024.
  • Median Interest & Investment Income over the past 3 years was $172000.0 (2023), compared with a mean of $512666.7.
  • Biggest five-year swings in Interest & Investment Income: plummeted 89.53% in 2024 and later soared 134300.0% in 2025.
  • Tonix Pharmaceuticals Holding's Interest & Investment Income stood at $7000.0 in 2023, then crashed by 85.71% to $1000.0 in 2024, then soared by 134300.0% to $1.3 million in 2025.
  • The last three reported values for Interest & Investment Income were $1.3 million (Q4 2025), $1.2 million (Q3 2025), and $943000.0 (Q2 2025) per Business Quant data.